

Program

Venue: Amstelzaal, VUmc, Amsterdam

Day 1 (3 December 2015) – Scientific program

- 8:30 – 9:30 Registration, Meet & Greet
9:30 – 9:40 Opening and Welcome, *Arjen Brussaard*

Session 1 – Opening Lecture

Session headed by Arjen Brussaard

- 9:40 – 10:30 *Opening lecture* - "Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders", *Mathias Jucker (University of Tübingen and German Center for Neurodegenerative Diseases)*

10:30 – 11:00 coffee break

Session 2 - Preclinical research and disease mechanisms

Session headed by Micha Wilhelmus

- 11:00 – 11:30 *Invited lecture* - Neurodegeneration and intracellular protein trafficking, *Casper Hoogenraad (Utrecht University)*
11.30 – 11.45 *Selected lecture* - The function of SERF in protein aggregation and Alzheimer disease, *Esther Stroo (University of Groningen)*
11:45 – 12:00 *Selected lecture* - Towards the understanding of the disease mechanism of vanishing white matter, *Truus Abbink (VUmc)*

Session 3 - Pecha Kucha

Session headed by Jeroen Hoozemans and Micha Wilhelmus

12:00 – 12:45 Short presentations of selected posters (7 min per presentation)

- 1) The molecular component of the neurodegenerative disorder spinocerebellar ataxia 19/22, *Claudio Tiecher (University of Groningen)*
- 2) Early-life stress modulates microglia function and Alzheimer's Disease neuropathology in APP^{swe}/PS1^{dE9} mice, *Lianne Hoeijmakers (University of Amsterdam)*
- 3) The effect of acute BACE1 inhibition on early cognitive deficits in a mouse model of A β toxicity, *Maarten Loos (Sylics, Amsterdam)*
- 4) A new *in vitro* model for C9orf72 ALS/FTD, *F.W. Riemsdijk (Erasmus MC)*
- 5) Improved CSF-based discrimination between Alzheimer patients and controls after correction for ventricular volumes, *Linda J.C. van Waalwijk van Doorn (Radboud University Medical Center)*
- 6) Gene-based analysis detects novel loci associated with frontotemporal dementia and its clinical subtypes, *Aniket Mishra (VUmc)*

12:45 – 14:30 Lunch and poster market

Session 4 - New biomarkers and therapy

Session headed by Jeroen Hoozemans

- 14:30 – 15:15 *Invited lecture* - The UPR as therapeutic target for neurodegeneration, *Giovanna Mallucci (University of Cambridge)*
- 15:15 – 15:30 *Selected lecture* - Cell-to-Cell Transmission of the Unfolded Protein Response and tau pathology, *Wiep Scheper (VU University Medical Center)*
- 15:30 – 15:45 *Selected lecture* - Role of TGF- β ETA pathway in hereditary Cerebral Amyloid Angiopathy, *Laure Grand Moursel (Leiden University Medical Center)*
- 15:45 – 16:00 *Selected lecture* - Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to AD, *A.E. Leeuwis (VUmc)*

16:00 – 16:30 Refreshment break

Session 5 - Towards Industry-Academia collaboration

Session headed by Bonno Bouma, Emeritus Professor, UMC Utrecht

- 16:30 – 16:50 Models for drug discovery, *Armand Tepper (Crossbeta Biosciences)*
- 16:50 – 17:10 Target discovery in the synapse, *Guus Smit (VU university)*
- 17:10 – 17:45 CNS drug development, *Chris Parsons (Merz Pharmaceuticals)*

17:45 – 20:00 Reception sponsored by Crossbeta Biosciences

Day 2 (4 December 2015) – Scientific & Industry Alliance Program

8:45 Welcome and introduction, *Arjen Brussaard & Wiesje van der Flier*

Session 6 - Scientific program (Memorabel projects¹)

Session headed by Wiesje van der Flier

- 9:00 – 9:15 Wiesje van der Flier (VUmc) – ABIDE: Alzheimer's Biomarkers in Daily Practice
- 9:15 – 9:30 Femke Bouwman (VUmc) – PAGE-AD: Pathological substrate of clinical variability in AD
- 9:30 – 9:45 Marcel Verbeek (Radboud UMC) – CAVIA: Cerebral Amyloid Angiopathy: Vascular Imaging and fluid markers of Amyloid deposition
- 9:45 – 10:00 Charlotte Teunissen (VUmc) – PRODIA: Development of biomarkers enabling early and accurate differential diagnosis of dementia
- 10:00 – 10:15 Kerensa Broersen (UTwente) – Exploring the potential of multi-target treatment for Alzheimer's disease: towards an integrated and transdisciplinary approach
- 10:15 – 10:30 Pilar Martinez (MUMC) – Sphingolipids: a novel target in the treatment of Alzheimer Disease?

10:30 – 11:00 coffee break

Session 7 - Towards interventions

Session headed by Arjen Brussaard

- 11:00 – 11:30 Disease interventions, *Stephan Schilling (Probiodrug)*
"Developing anti pGlu-Ab therapies - a differentiated Ab approach to treat Alzheimer's Disease"
- 11:30 – 12:00 Disease interventions, *Peter Lansbury (Lysosomal Therapeutics)*
"a divide and conquer approach to Parkinson's disease"
- 12:00 – 12:30 Perspective on industry academia collaboration, *John Allam (EIP Pharma)*
"Translational Medicine Success: The Importance of Committed and Enduring Academic-Industry Collaboration"
- 12:30 – 13:00 Clinical trials, *Philip Scheltens (Alzheimer Center Amsterdam)*
"50 ways to improve your clinical trial in AD"

13:00 – 14:00 Lunch, partnering and refreshment break

¹ Memorabel Projects = Scientific project supported by the Dutch Research Council (National Research Council N.W.O./ZONMW) on Neurodegeneration, involving industrial partnerships

Session 8 - Industry meets academia and affiliates

14:00-16:15 Round Table discussions (3 session of 40 minutes)

Round Table 1: Target Validation (Jeroen Hoozemans & Annemieke Rozemuller)

Round Table 2: Disease pathways (Pim van Nierop & Arjen Brussaard)

Round Table 3: iPS & Cellomics (Ruud Toonen & Ronald van Kesteren)

Round Table 4: PET and MRI imaging (Bart van Berckel & Hugo Vrenken/Mike Wattjes)

Round Table 5: Cognitive & functional measurements (Wiesje van der Flier & Roos Jutten)

Round Table 6: Clinical trial expertise & guidance (Philip Scheltens & Niels Prins)

16:15 - 17:00 Round up and panel discussion (with Probiodrug, Lysosomal Thx, EIPharma & NCA officials)

17:00 - 18:00 Drinks sponsored by Neuroscience Campus Amsterdam